A novel double antibody sandwich-lateral flow immunoassay for the rapid and simple detection of hepatitis C virus

International Journal of Molecular Medicine

Volumn 30, Issue 5, 2012, Pages 1041-1047

  Xiang, Tingxiu ^a   Jiang, Zheng ^a   Zheng, Jian ^b   Lo, Chaoyu ^b   Tsou, Harry ^b   Ren, Guosheng ^a   Zhang, Jun ^b   Huang, Ailong ^a   Lai, Guoqi ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b Artron BioResearch Inc   (Canada)

Author keywords

Colloidal gold; Double antibody sandwich lateral flow immunoassay; Hepatitis C virus; Recombinant protein

Indexed keywords

EPITOPE; HEPATITIS C ANTIBODY; RECOMBINANT ANTIGEN;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIGEN ANTIBODY COMPLEX; ANTIGEN PURIFICATION; ARTICLE; DOUBLE ANTIBODY SANDWICH LATERAL FLOW IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; HEPATITIS C VIRUS; IMMUNOASSAY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY; VIRUS DETECTION; VIRUS RECOMBINANT;

ANTIGENS, VIRAL; CLONING, MOLECULAR; ESCHERICHIA COLI; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; IMMUNOCHROMATOGRAPHY; IMMUNOLOGIC TESTS; PROTEIN BINDING; RECOMBINANT PROTEINS; SENSITIVITY AND SPECIFICITY; VIRAL PROTEINS;

EID: 84866635066     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.1121     Document Type: Article

References (21)

1. Nakamura J, Terajima K, Aoyagi Y and Akazawa K: Cost-effectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups. Tohoku J Exp Med 215: 33-42, 2008. (Pubitemid 351791266)
2. Belloni L, Moretti F, Merlo P, et al: DNp73alpha protects myogenic cells from apoptosis. Oncogene 25: 3606-3612, 2006. (Pubitemid 43901682)
3. Schuppan D, Krebs A, Bauer M and Hahn EG: Hepatitis C and liver fibrosis. Cell Death Differ 10 (Suppl 1): S59-S67, 2003. (Pubitemid 36511853)
4. Luo JC, Hwang SJ, Li CP, et al: Clinical significance of serum auto-antibodies in Chinese patients with chronic hepatitis C: negative role of serum viral titre and genotype. J Gastroenterol Hepatol 13: 475-479, 1998.
5. Schroeter M, Zoellner B, Polywka S, Laufs R and Feucht HH: Prolonged time until seroconversion among hemodialysis patients: the need for HCV PCR. Intervirology 48: 213-215, 2005. (Pubitemid 40827669)
6. Zaaijer HL, Cuypers HT, Reesink HW, Winkel IN, Gerken G and Lelie PN: Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet 341: 722-724, 1993. (Pubitemid 23085179)
7. Shahzamani K, Sabahi F, Merat S, et al: Rapid low-cost detection of hepatitis C virus RNA in HCV-infected patients by real-time RT-PCR using SYBR Green I. Arch Iran Med 14: 396-400, 2011.
8. Machnik G, Pelc E, Zapala M, et al: Designing and optimization of real-time RT-PCR technique for the detection of hepatitis C virus (HCV) genome in blood serum as internal laboratory quality control. Przegl Epidemiol 65: 325-332, 2011 (In Polish).
9. Gao Q, Liu D, Zhang S and Tong L: Analyses of anti-hCV detected by ELISA and HCV RNA detected by RT-nPCR in chronic hepatitis C virus infectors. Wei Sheng Yan Jiu 36: 69-71, 2007 (In Chinese).
10. Reddy AK, Dakshinamurty KV and Lakshmi V: Utility of HCV core antigen ELISA in the screening for hepatitis C virus infection in patients on hemodialysis. Indian J Med Microbiol 24: 55-57, 2006.
11. Rios M, Diago M, Rivera P, et al: Epidemiological, biological and histological characterization of patients with indeterminate third-generation recombinant immunoblot assay antibody results for hepatitis C virus. J Viral Hepat 13: 177-181, 2006.
12. Tung HD, Lu SN, Lee CM, et al: Antiviral treatment responses in patients with chronic hepatitis C virus infection evaluated by a third generation anti-hepatitis C virus assay. J Viral Hepat 9: 304-308, 2002.
13. Sookoian S and Castano G: Evaluation of a third generation anti-HCV assay in predicting viremia in patients with positive HCV antibodies. Ann Hepatol 1: 179-182, 2002.
14. Zhang J, Wang D, Li Y, et al: SARS coronavirus nucleocapsid protein monoclonal antibodies developed using a prokaryotic expressed protein. Hybridoma (Larchmt) 30: 481-485, 2011.
15. Goeser T, Muller HM, Ye J, Pfaff E and Theilmann L: Characterization of antigenic determinants in the core antigen of the hepatitis C virus. Virology 205: 462-469, 1994. (Pubitemid 24371687)
16. Beld M, Penning M, van Putten M, et al: Quantitative antibody responses to structural (Core) and nonstructural (NS3, NS4, and NS5) hepatitis C virus proteins among seroconverting injecting drug users: impact of epitope variation and relationship to detection of HCV RNA in blood. Hepatology 29: 1288-1298, 1999. (Pubitemid 29168767)
17. Hwang SJ: Hepatitis C virus infection: an overview. J Microbiol Immunol Infect 34: 227-234, 2001.
18. Nikolaeva LI, Blokhina NP, Tsurikova NN, et al: Virus-specific antibody titres in different phases of hepatitis C virus infection. J Viral Hepat 9: 429-437, 2002. (Pubitemid 35373764)
19. Jolivet-Reynaud C, Adida A, Michel S, et al: Characterization of mimotopes mimicking an immunodominant conformational epitope on the hepatitis C virus NS3 helicase. J Med Virol 72: 385-395, 2004. (Pubitemid 38133979)
20. Kato T, Miyamoto M, Furusaka A, et al: Processing of hepatitis C virus core protein is regulated by its C-terminal sequence. J Med Virol 69: 357-366, 2003. (Pubitemid 36158316)
21. Feucht HH, Zollner B, Polywka S and Laufs R: Study on reliability of commercially available hepatitis C virus antibody tests. J Clin Microbiol 33: 620-624, 1995.